NEWS

	May 31.2021
AVATAMED sets up Joint Service Lab with A*STAR’s Institute of Molecular and Cell Biology to offer Precision Oncology Services AVATAMED (www.avatamed.com), a precision medicine service company based in Singapore, announced the setting up of a joint lab with Singapore’s Institute of Molecular and Cell Biology (IMCB) at the Agency for Science, Technology and Research (A*STAR), to offer precision oncology services. Through this initiative, AVATAMED and IMCB aim to improve treatment outcome for cancer patients.   Globally, there are about 10 million cancer deaths every year and this number will increase over the years. Even with advances in new cancer therapeutics such as immunotherapy, and diagnostics such as genetic testing, there are still huge unmet needs of various groups of patients.   Precision oncology provides targeted treatment for individual cancer patients based on their clinical, tumour and genetic profiles. This approach has helped many patients whose tumours do not respond to the standard-of-care treatments, have limited treatment options or have become resistant to the anti-cancer drugs.   The joint service lab is located within IMCB’s premises at Proteos building in Biopolis, the heart of Singapore’s Biotechnology hub. Together with IMCB’s technological platforms such as the high-throughput drug screening platform, and expertise in cancer and cell biology, the joint service lab will offer AVATAMED’s proprietary drug screening technology, the AVATASCAN and its software to oncologists and pharmaceutical companies.   The AVATASCAN technology was born out of a decade of research at Samsung Medical Centre in South Korea, with accumulated drug response and genetic data of patient-derived tumours. The AVATASCAN screens the patient’s tumour samples across a panel of anti-cancer drugs to determine their efficacies in the patient-derived cells. These drug-response results, coupled with genetic data, are then presented to the oncologists to suggest drug treatment options. The AVATASCAN technology and database can also be utilised by pharmaceutical companies to accelerate their drug development through a more targeted approach.   “IMCB’s joint lab with AVATAMED will support Singapore’s move towards precision medicine-based treatments for better health outcomes. It also showcases our efforts in nurturing innovative local enterprises to drive economic growth,” said Professor Hong Wanjin, Executive Director of IMCB.   Mr Toh Hong Boon, CEO of AVATAMED, added, “AVATAMED is a spin-off from A*STAR, so we are delighted to be back at where it all started. Precision medicine is the future, and we want to bring AVATASCAN to benefit patients and the industry. We are excited to embark on this journey with A*STAR.”
	October 30.2020
AVATAMED and Macrogen sign MOU on joint business in personalized precision medicine services in cancer treatment We are excited to collaborate with Macrogen, a global precision medicine Company with the best-in-class genetic platform, in offering our Precision Medicine services! AVATAMED's drug screening technology (AVATASCAN), together with Macrogen's genetic platform, bring tremendous values to oncologists and their patients, as well as to the Pharmaceutical Industry.   For more information on the MOU, please refer to the attached Press Release.   From left: Macrogen Global Innovation Office SVP Dr. Bryan Sangjoon Hwang, Macrogen CEO Mr. Sukang Lee, AIMEDBIO CEO Prof. Do-Hyun Nam, Macrogen Chairman Dr. Jeong-Sun Seo, AVATAMED Application Scientist Ms. Miseol Son   From left: AVATAMED CEO Mr. Hong Boon Toh, Macrogen APAC CEO Dr. Kap-Seok Yang
	August 10.2020
AVATAMED Raises US$1 Million in Seed Funding We are pleased to announce the completion of our Seed Funding of US$1 million in March 2020.   We welcome Professor Pierce Chow, Senior Consultant at National Cancer Centre Singapore (NCCS), Professor Vinay Tergaonkar, Research Director at Institute of Molecular Cell Biology (IMCB) Singapore, Dr. Jae-Hoon Song, ex-President at Samsung Medical Centre, and Chung Joon, President at Solid Inc., as Board of Directors.   For more information of the Funding, please refer to the attached Press Release.   Also announced in the Press Release, in the fight against COVID-19, we launched AVATA Healthcare, www.avatahealthcare.com, to offer various infectious disease-related products to medical professionals, through our global network in the healthcare community.
	August 05.2020
AVATAMED Signed Distribution Agreement with BioTNS for the Sales of COVID-19 RT-PCR PNA Diagnostic Kits We are pleased to annouce the signing of a Distribution Agreement with BioTNS. This Agreement allows AVATAMED to offer the COVID-19 RT-PCR PNA Diagnostic Kits worldwide, and adds to AVATAMED growing portfolio of infectious disease-related Healthcare products.   Please view the Press Releases: http://www.sisanewszine.co.kr/news/articleView.html?idxno=11284 http://www.koreabiz.org/news/view.php?idx=26645&mcode=msub1   The molecular diagnostic kit developed by TNS is a reagent that amplifies and detects the amount of virus gene through reverse transcription polymerase chain reaction (RT-PCR), and has been approved for emergency use by the U.S. Food and Drug Administration (FDA). The biggest advantage of the COVID-19 PT-PCR PNA KIT is the improved sensitivity and precision by 2 to 5 times, compared to other diagnostic kits, resulting in very low false positives and false negatives.   Please visit www.avatahealthcare.com for more information.
	August 05.2020
AVATAMED Signed Contract with NanoFocusRay for overseas distribution of Mobile CT Phion 2.0 We are pleased to announce the signing of an overseas distributor contract for the the sales of NanoFocusRay Mobile CT Phion 2.0.   Please refer to press release: http://www.newsa.co.kr/news/articleView.html?idxno=253132 http://www.hrdnews.org/news/articleView.html?idxno=4849   Phion 2.0 is a portable CT that can be installed and operated anywhere, providing for quick examinations in the field that can relieve patients' anxety. Radiation dosage is also one-fourth that of a normal CT, reducing the patient's radiation exposure burden.   Phion 2.0 was originally developed for musculoskeletal and spinal imaging, but due to the COVID-19 pandemic, it was also certified by the South Korean Ministry of Food and Drug Safety (MFDS) on 11 March 2020 for the diagnosis of COVID-19 patients.   Please visit www.avatahealthcare.com for more information.
	July 10.2020
AVATAMED Partners CBmed in Europe on Precision Cancer Project We are pleased to annouce the partnership with CBmed in Europe on a Precision Cancer Project. Leveraging on AVATAMED's drug screening and genomic data analysis technology, the partnership will advance this joint effort to the rest of Europe through engagement with the oncology industry and pharmaceutical companies.
	July 01.2020
AVATAMED & Shinsung E&G, Winicare Signed Exclusive Sales Contract for "Smart Negative Pressure Isolation Room (NPIR) We are pleased to announce the signing of an exclusive sales contract with Shinsung E&G, Winicare to distribute Winicare's Smart Negative Pressure Isolation Room (NPIR) worldwide on 01 June 2020. AVATAMED is committed to assist healthcare professionals in the fight against COVID-19. This partnership allows us to offer a smart health technology solution to the healthcare industry through our global network.   For more information, please visit www.avatahealthcare.com.

May 31.2021 AVATAMED sets up Joint Service Lab with A*STAR’s Institute of Molecular and Cell Biology to offer Precision Oncology Services AVATAMED sets up Joint Service Lab with A*STAR’s Institute of Molecular and Cell Biology to offer Precision Oncology Services
October 30.2020 AVATAMED and Macrogen sign MOU on joint business in personalized precision medicine services in cancer treatment AVATAMED and Macrogen sign MOU on joint business in personalized precision medicine services in cancer treatment
August 10.2020 AVATAMED Raises US$1 Million in Seed Funding AVATAMED Raises US$1 Million in Seed Funding
August 05.2020 AVATAMED Signed Distribution Agreement with BioTNS for the Sales of COVID-19 RT-PCR PNA Diagnostic Kits AVATAMED Signed Distribution Agreement with BioTNS for the Sales of COVID-19 RT-PCR PNA Diagnostic Kits
August 05.2020 AVATAMED Signed Contract with NanoFocusRay for overseas distribution of Mobile CT Phion 2.0 AVATAMED Signed Contract with NanoFocusRay for overseas distribution of Mobile CT Phion 2.0
July 10.2020 AVATAMED Partners CBmed in Europe on Precision Cancer Project AVATAMED Partners CBmed in Europe on Precision Cancer Project
July 01.2020 AVATAMED & Shinsung E&G, Winicare Signed Exclusive Sales Contract for "Smart Negative Pressure Isolation Room (NPIR) AVATAMED & Shinsung E&G, Winicare Signed Exclusive Sales Contract for "Smart Negative Pressure Isolation Room (NPIR)